	US 11,969,432 B2
	Pharmaceutical composition and use thereof
Usso Barnas, Innsbruck (AT)
Filed by Usso Barnas, Innsbruck (AT)
Filed on Jun. 22, 2021, as Appl. No. 17/354,753.
Claims priority of application No. 20182558 (EP), filed on Jun. 26, 2020.
Prior Publication US 2021/0401854 A1, Dec. 30, 2021
Int. Cl. A61K 31/5513 (2006.01); A61K 9/00 (2006.01); A61K 31/135 (2006.01); A61K 31/196 (2006.01); A61K 31/197 (2006.01); A61K 31/4152 (2006.01); A61K 31/4415 (2006.01); A61K 31/455 (2006.01); A61K 31/525 (2006.01); A61K 31/542 (2006.01); A61K 31/573 (2006.01); A61K 31/714 (2006.01); A61P 25/04 (2006.01)

CPC A61K 31/5513 (2013.01) [A61K 9/0019 (2013.01); A61K 31/135 (2013.01); A61K 31/196 (2013.01); A61K 31/197 (2013.01); A61K 31/4152 (2013.01); A61K 31/4415 (2013.01); A61K 31/455 (2013.01); A61K 31/525 (2013.01); A61K 31/542 (2013.01); A61K 31/573 (2013.01); A61K 31/714 (2013.01); A61P 25/04 (2018.01)]

18 Claims

1. A pharmaceutical composition, wherein the pharmaceutical composition is an injectable or infusible pharmaceutical composition, comprising:

a) a pharmaceutically acceptable solvent,

b) a first active compound being an oxicam selected from lornoxicam or a pharmaceutically acceptable salt or solvate thereof,

c) a second active compound comprising metamizole or tramadol or a pharmaceutically acceptable salt or solvate thereof, and

d) a third active compound comprising at least one benzodiazepine or a pharmaceutically acceptable salt or solvate thereof,

wherein the pharmaceutical composition further comprises dexamethasone sodium, betamethasone sodium, methylprednisolone sodium, prednisolone sodium, or triamcinolone acetonide potassium.